BridgeBio Pharma, Inc. (NASDAQ:BBIO) to Post FY2027 Earnings of $2.56 Per Share, Leerink Partnrs Forecasts

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Stock analysts at Leerink Partnrs reduced their FY2027 EPS estimates for BridgeBio Pharma in a research report issued on Thursday, August 1st. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of $2.56 per share for the year, down from their prior estimate of $2.85. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.20) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s FY2028 earnings at $5.38 EPS.

Several other equities analysts have also commented on the stock. UBS Group dropped their price target on shares of BridgeBio Pharma from $51.00 to $47.00 and set a “buy” rating on the stock in a research note on Tuesday, May 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $70.00 target price on shares of BridgeBio Pharma in a research report on Monday, July 1st. HC Wainwright reissued a “buy” rating and issued a $43.00 price target on shares of BridgeBio Pharma in a research report on Monday. Bank of America dropped their price objective on BridgeBio Pharma from $50.00 to $42.00 and set a “buy” rating on the stock in a report on Tuesday, June 25th. Finally, Evercore ISI initiated coverage on shares of BridgeBio Pharma in a research report on Tuesday, May 14th. They set an “outperform” rating and a $50.00 target price on the stock. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $48.73.

BridgeBio Pharma Stock Performance

Shares of NASDAQ BBIO opened at $24.87 on Monday. The stock’s 50-day simple moving average is $26.69 and its 200-day simple moving average is $29.19. The firm has a market capitalization of $4.65 billion, a PE ratio of -7.72 and a beta of 1.06. BridgeBio Pharma has a fifty-two week low of $21.62 and a fifty-two week high of $44.32.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.61. The business had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $3.96 million. The firm’s quarterly revenue was up 32.1% on a year-over-year basis. During the same period last year, the firm earned ($0.98) earnings per share.

Insider Buying and Selling at BridgeBio Pharma

In other news, Director Randal W. Scott sold 1,000 shares of BridgeBio Pharma stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $28.84, for a total value of $28,840.00. Following the sale, the director now owns 5,500 shares of the company’s stock, valued at $158,620. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 24.66% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BridgeBio Pharma

A number of large investors have recently modified their holdings of the business. Bfsg LLC grew its holdings in BridgeBio Pharma by 175.6% during the second quarter. Bfsg LLC now owns 1,240 shares of the company’s stock worth $31,000 after acquiring an additional 790 shares during the period. YHB Investment Advisors Inc. acquired a new position in shares of BridgeBio Pharma during the 1st quarter worth $34,000. Quarry LP purchased a new position in shares of BridgeBio Pharma in the 4th quarter valued at about $50,000. EntryPoint Capital LLC purchased a new stake in BridgeBio Pharma during the first quarter worth about $117,000. Finally, Assetmark Inc. boosted its holdings in BridgeBio Pharma by 46.8% during the fourth quarter. Assetmark Inc. now owns 2,931 shares of the company’s stock worth $118,000 after buying an additional 935 shares in the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.